Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | tyrosine kinase | 0.0082 | 0.292 | 0.2988 |
Schistosoma mansoni | tyrosine kinase | 0.0082 | 0.292 | 0.2988 |
Toxoplasma gondii | fructose-bisphospatase II | 0.0155 | 0.9652 | 1 |
Echinococcus multilocularis | epidermal growth factor receptor | 0.0084 | 0.3127 | 0.32 |
Echinococcus granulosus | fructose 16 bisphosphatase 1 | 0.0155 | 0.9652 | 0.9876 |
Echinococcus granulosus | melanoma receptor tyrosine protein kinase | 0.0084 | 0.3127 | 0.32 |
Echinococcus granulosus | epidermal growth factor receptor | 0.0084 | 0.3127 | 0.32 |
Trypanosoma brucei | fructose-1,6-bisphosphatase | 0.0155 | 0.9652 | 1 |
Schistosoma mansoni | fructose-16-bisphosphatase-related | 0.0155 | 0.9652 | 0.9876 |
Brugia malayi | Furin-like cysteine rich region family protein | 0.0156 | 0.9773 | 1 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0155 | 0.9652 | 1 |
Echinococcus granulosus | epidermal growth factor receptor | 0.0156 | 0.9773 | 1 |
Leishmania major | 0.0155 | 0.9652 | 0.5 | |
Brugia malayi | ephrin receptor 1 precursor | 0.006 | 0.0858 | 0.0878 |
Loa Loa (eye worm) | fructose-1,6-bisphosphatase | 0.0155 | 0.9652 | 0.9652 |
Echinococcus multilocularis | insulin growth factor 1 receptor beta | 0.0055 | 0.0429 | 0.0438 |
Echinococcus granulosus | ephrin type A receptor 4 A | 0.0138 | 0.813 | 0.8319 |
Schistosoma mansoni | tyrosine kinase | 0.0084 | 0.3127 | 0.32 |
Loa Loa (eye worm) | hypothetical protein | 0.0123 | 0.6671 | 0.6671 |
Schistosoma mansoni | tyrosine kinase | 0.0082 | 0.292 | 0.2988 |
Echinococcus granulosus | insulin growth factor 1 receptor beta | 0.0055 | 0.0429 | 0.0438 |
Schistosoma mansoni | ephrin receptor | 0.0125 | 0.6878 | 0.7038 |
Echinococcus multilocularis | epidermal growth factor receptor | 0.0156 | 0.9773 | 1 |
Brugia malayi | fructose-1,6-bisphosphatase | 0.0155 | 0.9652 | 0.9876 |
Loa Loa (eye worm) | hypothetical protein | 0.0062 | 0.1079 | 0.1079 |
Echinococcus multilocularis | ephrin type A receptor 4 A | 0.0138 | 0.813 | 0.8319 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0155 | 0.9652 | 1 |
Schistosoma mansoni | tyrosine kinase | 0.0084 | 0.3127 | 0.32 |
Loa Loa (eye worm) | TK/EGFR protein kinase | 0.0156 | 0.9773 | 0.9773 |
Echinococcus multilocularis | fructose 1,6 bisphosphatase 1 | 0.0155 | 0.9652 | 0.9876 |
Onchocerca volvulus | 0.0123 | 0.6671 | 0.5 | |
Schistosoma mansoni | tyrosine kinase | 0.0156 | 0.9773 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | = 2.6 ug ml-1 | In vitro for antifungal activity against 10 yeasts | ChEMBL. | 9599237 |
MIC (functional) | = 40 ug ml-1 | In vitro antifungal activity against 6 filamentous fungi | ChEMBL. | 9599237 |
Protection (functional) | = 0 % | In vivo antifungal activity against murine candidosis model after peroral administration with 1 mg/kg at various time intervals.(percent protection for 100% mortality with untreated group) | ChEMBL. | 9599237 |
Protection (functional) | = 0 % | In vivo antifungal activity against murine candidosis model after peroral administration with 1 mg/kg at various time intervals.(percent protection for 100% mortality with fluconazole-treated group.) | ChEMBL. | 9599237 |
Protection (functional) | = 0 % | In vivo antifungal activity against murine candidosis model after peroral administration with 1 mg/kg at various time intervals.(percent protection for 100% mortality with untreated group) | ChEMBL. | 9599237 |
Protection (functional) | = 0 % | In vivo antifungal activity against murine candidosis model after peroral administration with 1 mg/kg at various time intervals.(percent protection for 100% mortality with fluconazole-treated group.) | ChEMBL. | 9599237 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.